Textbook of Medical Physiology

or exacerbates cir- thromboembolic conditions in people are usually twofold: culatory shock. It is partly for this reason that septicemic (1) a roughened endothelial surface of a vessel—as may be shock is lethal in 35% to 50% of patients. caused by arteriosclerosis, infection, or trauma—is likely A peculiar effect of disseminated intravascular coagu- to initiate the clotting process; and (2) blood often clots lation is that the patient, on occasion, begins to bleed. The when it flows very slowly through blood vessels, where reason for this bleeding is that so many of the clotting fac- small quantities of thrombin and other procoagulants are tors are removed by the widespread clotting that too few always being formed. procoagulants remain to allow normal hemostasis of the Use of Tissue Plasminogen Activator in Treating In- remaining blood. travascular Clots. Genetically engineered tissue plas- minogen activator (t- PA) is available. When delivered ANTICOAGULANTS FOR CLINICAL USE through a catheter to an area with a thrombus, it is effec- In some thromboembolic conditions, it is desirable to tive in activating plasminogen to plasmin, which in turn delay the coagulation process. Various anticoagulants can dissolve some intravascular clots. For example, if used have been developed for
